RPS6KA1(RSK1)
Sign in to save this workspaceUniProt Q15418 · PDB · AlphaFold · Substrate: Glycogen Synthase-derived peptide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 96.1% | 3.9% | 82.96 | 0.513 |
| 2 | Midostaurin | 95.5% | 4.5% | 78.64 | 0.500 |
| 3 | Netarsudil | 90.1% | 9.9% | 93.22 | 0.676 |
| 4 | Capivasertib | 88.8% | 11.2% | 96.48 | 0.644 |
| 5 | Rabusertib | 74.3% | 25.7% | 98.74 | 0.687 |
| 6 | Defactinib | 70.6% | 29.4% | 92.68 | 0.450 |
| 7 | Sunitinib | 68.9% | 31.1% | 91.73 | 0.524 |
| 8 | Ceritinib | 59.8% | 40.2% | 95.44 | 0.618 |
| 9 | Nintedanib | 56.2% | 43.8% | 90.23 | 0.608 |
| 10 | Gilteritinib | 49.1% | 50.9% | 88.97 | 0.506 |
| 11 | Darovasertib | 46.3% | 53.7% | 96.99 | 0.719 |
| 12 | Axitinib | 42.9% | 57.1% | 93.23 | 0.688 |
| 13 | Alectinib | 40.8% | 59.2% | 95.49 | 0.651 |
| 14 | Repotrectinib | 35.8% | 64.2% | 84.21 | 0.608 |
| 15 | Selpercatinib | 33.6% | 66.4% | 96.72 | 0.635 |
| 16 | Ripretinib | 32.4% | 67.6% | 92.95 | 0.674 |
| 17 | Lazertinib | 31.1% | 68.9% | 97.47 | 0.674 |
| 18 | Bosutinib | 27.4% | 72.6% | 87.22 | 0.555 |
| 19 | Abrocitinib | 22.6% | 77.4% | 99.50 | 0.581 |
| 20 | Pacritinib | 21.5% | 78.5% | 88.64 | 0.452 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.05
- Epithelial log2(TPM+1): 4.46
- Fold change: -1.41
- Status: Downregulated
Selectivity landscape vs inhibition on RPS6KA1
Each point is one of the 92 approved drugs; color = inhibition % on RPS6KA1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…